share_log

Benchmark Upgrades Emergent BioSolutions to Buy, Announces $22 Price Target

Benchmark Upgrades Emergent BioSolutions to Buy, Announces $22 Price Target

Benchmark 將Emergent BioSolutions上調至買入,宣佈
Benzinga ·  2023/04/10 06:57

Benchmark analyst Robert Wasserman upgrades Emergent BioSolutions (NYSE:EBS) from Hold to Buy and announces $22 price target.

基準分析師羅伯特·瓦瑟曼將Emergent BioSolutions(紐約證券交易所代碼:EBS)從持有上調至買入,並宣佈了22美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論